Genentech's Lymphoma Drug Combo Wows in Mid-Stage Trial Post author:Sam Post published:December 10, 2017 Post category:BioPharma These data led to FDA Breakthrough Therapy and EMA PRIME (PRIority MEdicines) designations. Source: BioSpace You Might Also Like Atossa Genetics Announces First Quarter 2017 Financial Results And Provides Company Update May 15, 2017 Xenex Locks in $38 Million in Funding February 23, 2017 Hanmi Pharma Charged for Failure to Report Patient Death in Olmutinib Study April 17, 2017
Atossa Genetics Announces First Quarter 2017 Financial Results And Provides Company Update May 15, 2017